Alumis (ALMS) Revenue Quarterly: History & Chart

Alumis Inc.(ALMS)

Biotechnology · South San Francisco, CA

$6.84-0.01 (-0.15%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Alumis Inc.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

South San Francisco, CA

237 employees

www.alumis.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martin Babler

View full financials

Quarterly Revenue

Basis: latest reported fiscal quarter (Q2 FY2026). Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly revenue is $1.66M with QoQ Growth of (4.54%). Quarterly revenue is the total sales generated during the latest fiscal quarter.

Revenue TTM|Revenue Annual|Revenue CAGR|Financials

Quarterly Revenue

ALMS Quarterly Revenue

$1.66M

Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $1.66M.

ALMS P/S Ratio

Full P/S Ratio page

P/S Ratio

ALMS P/S Ratio Chart

114.12

FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:01:09.574Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

ALMS EV/Sales

Full EV/Sales page

EV/Sales

ALMS EV/Sales Chart

110.43x

Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T13:01:09.574Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

Quarterly Revenue History

Period	Quarterly Revenue	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$1.66M	(4.54%)	(37.66%)
Q1 FY2026Period end 2026-03-31	$1.74M	(9.75%)	(89.99%)
Q4 FY2025Period end 2025-12-31	$1.93M	(6.63%)	N/A
Q3 FY2025Period end 2025-09-30	$2.07M	(22.51%)	N/A
Q2 FY2025Period end 2025-06-30	$2.67M	(84.67%)	N/A
Q1 FY2025Period end 2025-03-31	$17.39M	N/A	N/A
Q4 FY2024Period end 2024-12-31	$0	N/A	N/A
Q3 FY2024Period end 2024-09-30	$0	N/A	N/A
Q2 FY2024Period end 2024-06-30	$0	N/A	N/A
Q1 FY2024Period end 2024-03-31	$0	N/A	N/A
Q4 FY2023Period end 2023-12-31	$0	N/A	N/A
Q3 FY2023Period end 2023-09-30	$0	N/A	N/A
Q2 FY2023Period end 2023-06-30	$0	N/A	N/A
Q1 FY2023Period end 2023-03-31	$0	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.